Kaleo Logo


Media Contact

Caryn Foster Durham
Senior Director, Corporate Communications
(804) 545-6360

Media Contact

Caryn Foster Durham
Senior Director, Corporate Communications
(804) 545-6360

News Archive

Accent Lines
December 21, 2020

Kaléo Expands Executive Team with New Appointments

August 18, 2020

The Upcoming School Year is Expected to be Fraught with Uncertainty, Particularly for Children with Life-Threatening Food Allergies

August 10, 2020

Kaléo and the pan-Canadian Pharmaceutical Alliance (pCPA) Complete Negotiations for ALLERJECT® (epinephrine injection, USP) Auto-Injector for the Treatment of Serious Allergic Reactions Across Canadian Provinces

August 10, 2020

Kaléo et l’Alliance pancanadienne pharmaceutique (APP) concluent leurs négociations sur l’auto-injecteur ALLERJECT® (épinéphrine injectable, USP) destiné au traitement des réactions allergiques graves dans les différentes provinces canadiennes.

May 12, 2020

Kaléo Announces ALLERJECT® (epinephrine injection, USP) Auto-Injector Will Be Available for Canadians at Risk for Anaphylaxis Starting May 19, 2020

May 12, 2020

Kaléo annonce qu’à partir du 19 mai 2020 l’auto-injecteur ALLERJECT® (épinéphrine injectable, USP) sera à la disposition des Canadiens à risque d’anaphylaxie.

July 11, 2019

Walgreens and Kaléo Expand Retail Pharmacy Collaboration to Include AUVI-q® (epinephrine injection, USP) 0.1 mg, the Only FDA-Approved Epinephrine Auto-Injector for Infants and Toddlers, 16.5 – 33 lbs

December 12, 2018

Authorized Generic for EVZIO® (naloxone HCl injection) to be Available at a Reduced List Price of $178

September 6, 2018

Walgreens and Kaléo Partner to Address Epinephrine Auto-Injector Supply Issues, Providing Patients Access to AUVI-Q® (epinephrine injection, USP) Through Walgreens Locations Nationwide

August 29, 2018

AUVI-Q® (epinephrine injection, USP) Available in Canada Starting September 7

August 14, 2018

Kaléo Confirms U.S. Availability of AUVI-Q® (epinephrine injection, USP) Auto-injector for Back-to-School Season

April 26, 2018

With Life-Threatening Allergies Diagnosed in Infancy, Kaléo Announces Availability of First and Only FDA-Approved Epinephrine Auto-Injector (EAI) for Infants and Toddlers Weighing 16.5 to 33 Pounds (7.5 to 15 kilograms)

April 18, 2018

NASCAR Driver Elliott Sadler Teams Up with Kaléo about AUVI-Q® (Epinephrine Injection, USP) to Raise Awareness of Life-Threatening Allergies

April 5, 2018

EVZIO® (naloxone HCl injection, USP) Auto-Injector Now Available to Patients in Select States Without a Prescription Through Kaléo’s New Virtual Standing Order Pilot Program and to Government Agencies at a Direct Purchase Price

February 21, 2018

Cabell-Huntington Health Department and the City of Huntington Fire Department Officials Named Co-Recipients of the 2017 Kaléo Cares Award

January 11, 2018

More than 5000 Lives Reported Saved with Help of EVZIO® (naloxone HCl injection) Auto-injectors

November 20, 2017

U.S. FDA Approves Kaléo’s AUVI-Q® (Epinephrine Injection, USP) 0.1 mg Auto-Injector for Life-Threatening Allergic Reactions in Infants and Small Children

October 24, 2017

Kaléo Along with National Advocacy Organizations Launch the “No Appetite for Bullying” Initiative

1 2 3